<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01253265</url>
  </required_header>
  <id_info>
    <org_study_id>13061</org_study_id>
    <secondary_id>I1F-JE-RHAL</secondary_id>
    <nct_id>NCT01253265</nct_id>
  </id_info>
  <brief_title>A Study in Rheumatoid Arthritis</brief_title>
  <official_title>Multiple-Dose, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY2439821 in Japanese Patients With Rheumatoid Arthritis on Concomitant Methotrexate Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of multiple doses of
      LY2439821 in Japanese patients with rheumatoid arthritis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Effects</measure>
    <time_frame>Baseline up to 26 weeks</time_frame>
    <description>Clinically significant events were defined as serious and other non-serious adverse events. A summary of serious and all other non-serious adverse events is located in the Reported Adverse Event module.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline to 16 Week Endpoint in C-Reactive Protein</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
    <description>C-reactive protein (CRP) is a disease related biomarker and measured in milligrams per liter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline to 16 Week Endpoint in Erythrocyte Sedimentation Rate (ESR)</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
    <description>Erythrocyte Sedimentation Rate (ESR) is a disease related biomarker and measured in millimeters per hour (mm/h).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 26 Week Endpoint in Neutrophil Counts</measure>
    <time_frame>Baseline, 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 26 Week Endpoint in Lymphocyte Counts</measure>
    <time_frame>Baseline, 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Area Under the Concentration-time Curve (AUC) at Steady State (ss)</measure>
    <time_frame>Week 10 pre-dose up to 2 weeks post-dose (Week 12)</time_frame>
    <description>AUCτ,ss= area under the concentration versus time curve (τ) at steady state (ss)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Maximum Plasma Drug Concentration (Cmax) at Steady State (ss)</measure>
    <time_frame>Week 10 pre-dose up to 2 weeks post-dose (Week 12)</time_frame>
    <description>Cmax,ss = maximum observed drug concentration (Cmax) at steady state (ss)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Time of Maximum Observed Drug Concentration (Tmax) at Steady State (ss)</measure>
    <time_frame>Week 10 pre-dose up to 2 weeks post-dose (Week 12)</time_frame>
    <description>tmax,ss = time of maximum observed drug concentration (tmax) at steady state (ss)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>30 mg LY2439821</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>80 mg LY2439821</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>180 mg LY2439821</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo is administered subcutaneously in the same manner as active drug in each dose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>120 mg LY2439821</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered subcutaneously at 240 mg as a single loading dose followed by 120 mg every week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2439821</intervention_name>
    <description>Administered subcutaneously</description>
    <arm_group_label>30 mg LY2439821</arm_group_label>
    <arm_group_label>80 mg LY2439821</arm_group_label>
    <arm_group_label>180 mg LY2439821</arm_group_label>
    <arm_group_label>120 mg LY2439821</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered subcutaneously</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ambulatory male or female patients between the ages of 20 and 75 years

          -  Male patients: Agree to use a reliable method of birth control during the study
             including barrier contraceptives or a monogamous relationship with a partner who is
             not child bearing. Female patients: Are women who test negative for pregnancy at the
             time of entry based on a pregnancy test and are not breast feeding. Women of child
             bearing potential must agree to use a reliable method of birth control during the
             study.

          -  Patients who are between the body weight of 40 and 105 kilogram (kg)

          -  Patients who have an established diagnosis of Rheumatoid Arthritis (RA)

          -  Patients who have C reactive protein (CRP) measurement greater than the upper limit of
             normal or erythrocyte sedimentation rate of at least 28 millimeters per hour (mm/hr)

          -  Patients who have been treated with regular use of Methotrexate (MTX) for at least 12
             weeks, and stable treatment (at least 7.5 milligrams per week (mg/week)) for at least
             8 weeks

          -  Patients who have given written informed consent approved by the Sponsor and the
             Institutional Review Board (IRB) governing the investigational site

          -  Patients who have reliable and willing to make themselves available for the duration
             of the study and are willing to follow study procedures

        Exclusion Criteria:

          -  Patients who use oral corticosteroids at average daily doses of &gt;10 mg/day of
             prednisone or its equivalent or use of variable doses of oral corticosteroids within
             the last 4 weeks

          -  Patients who have had a live vaccination within the last 12 weeks, or intend to have a
             live vaccination during the course of the study, or have participated in a vaccine
             clinical study within the last 12 weeks

          -  Patients who have a diagnosis of any systemic inflammatory condition other than RA

          -  Patients who have evidence of active vasculitis or uveitis

          -  Patients who have a diagnosis of Felty's syndrome

          -  Patients who have had surgical treatment of a joint within the last 8 weeks, or will
             require it during the study

          -  Patients who have had lymphoma, leukemia, or any malignancy within the last 5 years
             except for basal cell or squamous epithelial carcinomas of the skin that have been
             resected with no evidence of metastatic disease

          -  Patients who have suffered a serious bacterial infection within the last 12 weeks, or
             a recent or ongoing infection

          -  Patients who have an evidence or suspicion of active tuberculosis (TB) by medical
             history, physical examination, and/or chest radiograph or documentation of TB by a
             positive purified protein derivative (PPD) test

          -  Patients who have uncontrolled arterial hypertension characterized by a systolic blood
             pressure &gt;160 mmHg or diastolic blood pressure &gt;100 mmHg

          -  Patients who have an evidence of positive hepatitis B (HBV) surface antigen, positive
             hepatitis B surface antibody, positive hepatitis B core antibody, or hepatitis B DNA
             (HBV DNA); an evidence of human immunodeficiency virus (HIV), evidence of hepatitis B;
             or an evidence of hepatitis C

          -  Patients who have clinical laboratory test results at entry that are outside the
             normal reference range, or results with unacceptable deviations that are considered
             clinically significant by the investigator

          -  Patients who have a serum creatinine &gt;2.0 milligrams per deciliter (mg/dL)

          -  Patients who have known hypogammaglobulinemia or a serum immunoglobulin (Ig) G (IgG),
             IgM, or IgA concentration less than the lower limit of normal

          -  Patients who have an abnormality in the 12 lead electrocardiogram (ECG).

          -  Patients who have donated of blood more than 200 mL within the past 30 days, or more
             than 400 milliliters (mL) within the past 90 days

          -  Patients who are currently enrolled in, or discontinued within the last 30 days from,
             a clinical trial involving an off label use of an investigational drug or device, or
             are concurrently enrolled in any other type of medical research judged not to be
             scientifically or medically compatible with this study. For unapproved
             Disease-Modifying Anti-Rheumatic Drug (DMARDs), have received 30 days or 5 fold of the
             half life prior to inclusion whichever is longer

          -  Patients who previously completed or withdrawn from this study or any other study
             investigating LY2439821

          -  Patients who have been treated with any biologic DMARD currently or previously for 5
             half lives

          -  Patients who have had serious reaction to other biologic Disease-Modifying
             Anti-Rheumatic Drug (DMARDs)

          -  Patients who have received non biologics DMARDs (other than MTX, sulfasalazine,
             bucillamine or hydroxychloroquine)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fukuoka</city>
        <zip>820-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hyogo</city>
        <zip>673-1462</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ibaragi</city>
        <zip>316-0035</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nagasaki</city>
        <zip>857-1165</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Niigata</city>
        <zip>940-2085</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Okayama</city>
        <zip>712-8044</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shimane</city>
        <zip>699-0293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tokyo</city>
        <zip>164-8541</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2010</study_first_submitted>
  <study_first_submitted_qc>December 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2010</study_first_posted>
  <results_first_submitted>April 20, 2016</results_first_submitted>
  <results_first_submitted_qc>April 20, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 26, 2016</results_first_posted>
  <last_update_submitted>April 20, 2016</last_update_submitted>
  <last_update_submitted_qc>April 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ixekizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>30 Milligram (mg) LY2439821</title>
          <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
        </group>
        <group group_id="P2">
          <title>80 mg LY2439821</title>
          <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
        </group>
        <group group_id="P3">
          <title>180 mg LY2439821</title>
          <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
        </group>
        <group group_id="P4">
          <title>120 mg LY2439821</title>
          <description>240 mg LY2439821 was administered subcutaneously (loading dose) at Week 0, followed by 120 mg LY2439821 administered subcutaneously weekly from Week 1 through Week 10</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Placebo is administered subcutaneously in the same manner as active drug in each dose group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Met Predefined Discontinuation Criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>30 mg LY2439821</title>
          <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
        </group>
        <group group_id="B2">
          <title>80 mg LY2439821</title>
          <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
        </group>
        <group group_id="B3">
          <title>180 mg LY2439821</title>
          <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
        </group>
        <group group_id="B4">
          <title>120 mg LY2439821</title>
          <description>240 mg LY2439821 was administered subcutaneously (loading dose) at Week 0, followed by 120 mg LY2439821 administered subcutaneously weekly from Week 1 through Week 10</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Placebo is administered subcutaneously in the same manner as active drug in each dose group</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.0" spread="15.4"/>
                    <measurement group_id="B2" value="56.8" spread="7.2"/>
                    <measurement group_id="B3" value="61.7" spread="11.3"/>
                    <measurement group_id="B4" value="52.5" spread="14.0"/>
                    <measurement group_id="B5" value="60.1" spread="7.7"/>
                    <measurement group_id="B6" value="57.0" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>C-Reactive Protein (CRP)</title>
          <units>milligrams per liter (mg/L)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.950" lower_limit="5.00" upper_limit="25.10"/>
                    <measurement group_id="B2" value="11.750" lower_limit="2.00" upper_limit="50.10"/>
                    <measurement group_id="B3" value="3.500" lower_limit="2.80" upper_limit="12.80"/>
                    <measurement group_id="B4" value="31.000" lower_limit="9.30" upper_limit="95.20"/>
                    <measurement group_id="B5" value="5.650" lower_limit="1.10" upper_limit="50.10"/>
                    <measurement group_id="B6" value="9.700" lower_limit="1.10" upper_limit="95.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Erythrocyte Sedimentation Rate (ESR)</title>
          <units>millimeters per hour (mm/h)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.0" lower_limit="7" upper_limit="87"/>
                    <measurement group_id="B2" value="53.5" lower_limit="23" upper_limit="107"/>
                    <measurement group_id="B3" value="26.0" lower_limit="4" upper_limit="50"/>
                    <measurement group_id="B4" value="42.5" lower_limit="22" upper_limit="81"/>
                    <measurement group_id="B5" value="25.5" lower_limit="9" upper_limit="48"/>
                    <measurement group_id="B6" value="29.5" lower_limit="4" upper_limit="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Neutrophils</title>
          <units>10^9 cells per liter (GI/L)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.763" lower_limit="3.13" upper_limit="7.67"/>
                    <measurement group_id="B2" value="4.293" lower_limit="2.59" upper_limit="11.12"/>
                    <measurement group_id="B3" value="3.857" lower_limit="2.59" upper_limit="5.26"/>
                    <measurement group_id="B4" value="6.056" lower_limit="4.63" upper_limit="7.56"/>
                    <measurement group_id="B5" value="6.757" lower_limit="4.14" upper_limit="8.97"/>
                    <measurement group_id="B6" value="5.261" lower_limit="2.59" upper_limit="11.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lymphocytes</title>
          <units>10^9 cells per liter (GI/L)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.993" lower_limit="0.42" upper_limit="2.62"/>
                    <measurement group_id="B2" value="1.156" lower_limit="0.69" upper_limit="2.19"/>
                    <measurement group_id="B3" value="1.187" lower_limit="0.88" upper_limit="2.01"/>
                    <measurement group_id="B4" value="1.379" lower_limit="0.67" upper_limit="2.45"/>
                    <measurement group_id="B5" value="1.295" lower_limit="1.06" upper_limit="2.29"/>
                    <measurement group_id="B6" value="1.275" lower_limit="0.42" upper_limit="2.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Rheumatoid Arthritis (RA)</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.9" spread="11.8"/>
                    <measurement group_id="B2" value="7.9" spread="9.7"/>
                    <measurement group_id="B3" value="6.8" spread="12.0"/>
                    <measurement group_id="B4" value="5.6" spread="4.1"/>
                    <measurement group_id="B5" value="3.6" spread="3.2"/>
                    <measurement group_id="B6" value="6.8" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weekly dose of Methotrexate (MTX)</title>
          <units>milligrams per week (mg/wk)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.33" spread="0.82"/>
                    <measurement group_id="B2" value="8.33" spread="0.82"/>
                    <measurement group_id="B3" value="8.00" spread="0.00"/>
                    <measurement group_id="B4" value="9.00" spread="1.10"/>
                    <measurement group_id="B5" value="9.06" spread="1.66"/>
                    <measurement group_id="B6" value="8.58" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Effects</title>
        <description>Clinically significant events were defined as serious and other non-serious adverse events. A summary of serious and all other non-serious adverse events is located in the Reported Adverse Event module.</description>
        <time_frame>Baseline up to 26 weeks</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>30 mg LY2439821</title>
            <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
          </group>
          <group group_id="O2">
            <title>80 mg LY2439821</title>
            <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
          </group>
          <group group_id="O3">
            <title>180 mg LY2439821</title>
            <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
          </group>
          <group group_id="O4">
            <title>120 mg LY2439821</title>
            <description>240 mg LY2439821 was administered subcutaneously (loading dose) at Week 0, followed by 120 mg LY2439821 administered subcutaneously weekly from Week 1 through Week 10</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo is administered subcutaneously in the same manner as active drug in each dose group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Effects</title>
          <description>Clinically significant events were defined as serious and other non-serious adverse events. A summary of serious and all other non-serious adverse events is located in the Reported Adverse Event module.</description>
          <population>All randomized participants.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline to 16 Week Endpoint in C-Reactive Protein</title>
        <description>C-reactive protein (CRP) is a disease related biomarker and measured in milligrams per liter.</description>
        <time_frame>Baseline, 16 weeks</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>30 mg LY2439821</title>
            <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
          </group>
          <group group_id="O2">
            <title>80 mg LY2439821</title>
            <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
          </group>
          <group group_id="O3">
            <title>180 mg LY2439821</title>
            <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
          </group>
          <group group_id="O4">
            <title>120 mg LY2439821</title>
            <description>240 mg LY2439821 was administered subcutaneously (loading dose) at Week 0, followed by 120 mg LY2439821 administered subcutaneously weekly from Week 1 through Week 10</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo is administered subcutaneously in the same manner as active drug in each dose group</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline to 16 Week Endpoint in C-Reactive Protein</title>
          <description>C-reactive protein (CRP) is a disease related biomarker and measured in milligrams per liter.</description>
          <population>All randomized participants.</population>
          <units>percentage change in C-Reactive Protein</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-88.75" lower_limit="-98.6" upper_limit="-66.7"/>
                    <measurement group_id="O2" value="-73.81" lower_limit="-98.8" upper_limit="180.0"/>
                    <measurement group_id="O3" value="-17.04" lower_limit="-48.4" upper_limit="150.0"/>
                    <measurement group_id="O4" value="-95.47" lower_limit="-99.3" upper_limit="100.0"/>
                    <measurement group_id="O5" value="-8.07" lower_limit="-82.8" upper_limit="186.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline to 16 Week Endpoint in Erythrocyte Sedimentation Rate (ESR)</title>
        <description>Erythrocyte Sedimentation Rate (ESR) is a disease related biomarker and measured in millimeters per hour (mm/h).</description>
        <time_frame>Baseline, 16 weeks</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>30 mg LY2439821</title>
            <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
          </group>
          <group group_id="O2">
            <title>80 mg LY2439821</title>
            <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
          </group>
          <group group_id="O3">
            <title>180 mg LY2439821</title>
            <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
          </group>
          <group group_id="O4">
            <title>120 mg LY2439821</title>
            <description>240 mg LY2439821 was administered subcutaneously (loading dose) at Week 0, followed by 120 mg LY2439821 administered subcutaneously weekly from Week 1 through Week 10</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo is administered subcutaneously in the same manner as active drug in each dose group</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline to 16 Week Endpoint in Erythrocyte Sedimentation Rate (ESR)</title>
          <description>Erythrocyte Sedimentation Rate (ESR) is a disease related biomarker and measured in millimeters per hour (mm/h).</description>
          <population>All randomized participants.</population>
          <units>percentage change in ESR</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.50" lower_limit="-80.0" upper_limit="-16.7"/>
                    <measurement group_id="O2" value="-35.05" lower_limit="-76.1" upper_limit="13.3"/>
                    <measurement group_id="O3" value="-3.75" lower_limit="-37.9" upper_limit="100.0"/>
                    <measurement group_id="O4" value="-73.08" lower_limit="-92.7" upper_limit="-5.6"/>
                    <measurement group_id="O5" value="-12.62" lower_limit="-54.5" upper_limit="137.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 26 Week Endpoint in Neutrophil Counts</title>
        <time_frame>Baseline, 26 weeks</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>30 mg LY2439821</title>
            <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
          </group>
          <group group_id="O2">
            <title>80 mg LY2439821</title>
            <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
          </group>
          <group group_id="O3">
            <title>180 mg LY2439821</title>
            <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
          </group>
          <group group_id="O4">
            <title>120 mg LY2439821</title>
            <description>240 mg LY2439821 was administered subcutaneously (loading dose) at Week 0, followed by 120 mg LY2439821 administered subcutaneously weekly from Week 1 through Week 10</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo is administered subcutaneously in the same manner as active drug in each dose group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 26 Week Endpoint in Neutrophil Counts</title>
          <population>All randomized participants.</population>
          <units>10^9 cells per liter (GI/L)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.681" lower_limit="-5.77" upper_limit="5.84"/>
                    <measurement group_id="O2" value="-0.559" lower_limit="-2.62" upper_limit="5.62"/>
                    <measurement group_id="O3" value="-0.170" lower_limit="-0.87" upper_limit="2.72"/>
                    <measurement group_id="O4" value="-2.677" lower_limit="-2.87" upper_limit="-0.70"/>
                    <measurement group_id="O5" value="-0.641" lower_limit="-2.94" upper_limit="2.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 26 Week Endpoint in Lymphocyte Counts</title>
        <time_frame>Baseline, 26 weeks</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>30 mg LY2439821</title>
            <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
          </group>
          <group group_id="O2">
            <title>80 mg LY2439821</title>
            <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
          </group>
          <group group_id="O3">
            <title>180 mg LY2439821</title>
            <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
          </group>
          <group group_id="O4">
            <title>120 mg LY2439821</title>
            <description>240 mg LY2439821 was administered subcutaneously (loading dose) at Week 0, followed by 120 mg LY2439821 administered subcutaneously weekly from Week 1 through Week 10</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo is administered subcutaneously in the same manner as active drug in each dose group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 26 Week Endpoint in Lymphocyte Counts</title>
          <population>All randomized participants.</population>
          <units>10^9 cells per liter (GI/L)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.189" lower_limit="-1.19" upper_limit="1.23"/>
                    <measurement group_id="O2" value="-0.011" lower_limit="-0.54" upper_limit="1.25"/>
                    <measurement group_id="O3" value="-0.184" lower_limit="-0.37" upper_limit="0.09"/>
                    <measurement group_id="O4" value="0.138" lower_limit="-0.15" upper_limit="0.65"/>
                    <measurement group_id="O5" value="0.085" lower_limit="-0.56" upper_limit="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics - Area Under the Concentration-time Curve (AUC) at Steady State (ss)</title>
        <description>AUCτ,ss= area under the concentration versus time curve (τ) at steady state (ss)</description>
        <time_frame>Week 10 pre-dose up to 2 weeks post-dose (Week 12)</time_frame>
        <population>All randomized participants with analyzable pharmacokinetic data.</population>
        <group_list>
          <group group_id="O1">
            <title>30 mg LY2439821</title>
            <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
          </group>
          <group group_id="O2">
            <title>80 mg LY2439821</title>
            <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
          </group>
          <group group_id="O3">
            <title>180 mg LY2439821</title>
            <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
          </group>
          <group group_id="O4">
            <title>120 mg LY2439821</title>
            <description>240 mg LY2439821 was administered subcutaneously (loading dose) at Week 0, followed by 120 mg LY2439821 administered subcutaneously weekly from Week 1 through Week 10</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics - Area Under the Concentration-time Curve (AUC) at Steady State (ss)</title>
          <description>AUCτ,ss= area under the concentration versus time curve (τ) at steady state (ss)</description>
          <population>All randomized participants with analyzable pharmacokinetic data.</population>
          <units>micrograms•day per milliliter(μg•day/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.2" spread="26"/>
                    <measurement group_id="O2" value="151" spread="44"/>
                    <measurement group_id="O3" value="437" spread="42"/>
                    <measurement group_id="O4" value="208" spread="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics - Maximum Plasma Drug Concentration (Cmax) at Steady State (ss)</title>
        <description>Cmax,ss = maximum observed drug concentration (Cmax) at steady state (ss)</description>
        <time_frame>Week 10 pre-dose up to 2 weeks post-dose (Week 12)</time_frame>
        <population>All randomized participants with analyzable pharmacokinetic data.</population>
        <group_list>
          <group group_id="O1">
            <title>30 mg LY2439821</title>
            <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
          </group>
          <group group_id="O2">
            <title>80 mg LY2439821</title>
            <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
          </group>
          <group group_id="O3">
            <title>180 mg LY2439821</title>
            <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
          </group>
          <group group_id="O4">
            <title>120 mg LY2439821</title>
            <description>240 mg LY2439821 was administered subcutaneously (loading dose) at Week 0, followed by 120 mg LY2439821 administered subcutaneously weekly from Week 1 through Week 10</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics - Maximum Plasma Drug Concentration (Cmax) at Steady State (ss)</title>
          <description>Cmax,ss = maximum observed drug concentration (Cmax) at steady state (ss)</description>
          <population>All randomized participants with analyzable pharmacokinetic data.</population>
          <units>micrograms per milliliter (μg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.05" spread="26"/>
                    <measurement group_id="O2" value="13.5" spread="43"/>
                    <measurement group_id="O3" value="39.3" spread="42"/>
                    <measurement group_id="O4" value="33.1" spread="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics - Time of Maximum Observed Drug Concentration (Tmax) at Steady State (ss)</title>
        <description>tmax,ss = time of maximum observed drug concentration (tmax) at steady state (ss)</description>
        <time_frame>Week 10 pre-dose up to 2 weeks post-dose (Week 12)</time_frame>
        <population>All randomized participants with analyzable pharmacokinetic data.</population>
        <group_list>
          <group group_id="O1">
            <title>30 mg LY2439821</title>
            <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
          </group>
          <group group_id="O2">
            <title>80 mg LY2439821</title>
            <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
          </group>
          <group group_id="O3">
            <title>180 mg LY2439821</title>
            <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
          </group>
          <group group_id="O4">
            <title>120 mg LY2439821</title>
            <description>240 mg LY2439821 was administered subcutaneously (loading dose) at Week 0, followed by 120 mg LY2439821 administered subcutaneously weekly from Week 1 through Week 10</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics - Time of Maximum Observed Drug Concentration (Tmax) at Steady State (ss)</title>
          <description>tmax,ss = time of maximum observed drug concentration (tmax) at steady state (ss)</description>
          <population>All randomized participants with analyzable pharmacokinetic data.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" lower_limit="1.91" upper_limit="7.00"/>
                    <measurement group_id="O2" value="1.93" lower_limit="1.89" upper_limit="3.97"/>
                    <measurement group_id="O3" value="1.95" lower_limit="1.88" upper_limit="2.02"/>
                    <measurement group_id="O4" value="3.89" lower_limit="1.93" upper_limit="3.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>30 mg LY2439821</title>
          <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
        </group>
        <group group_id="E2">
          <title>80 mg LY2439821</title>
          <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
        </group>
        <group group_id="E3">
          <title>180 mg LY2439821</title>
          <description>Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10</description>
        </group>
        <group group_id="E4">
          <title>120 mg LY2439821</title>
          <description>240 mg LY2439821 was administered subcutaneously (loading dose) at Week 0, followed by 120 mg LY2439821 administered subcutaneously weekly from Week 1 through Week 10</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Placebo is administered subcutaneously in the same manner as active drug in each dose group</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Administration site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Molluscum contagiosum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Heat illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menopausal symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pain prophylaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

